AlzProtect starts a new clinical study on the absorption of AZP2006 according to food intake

September, 19 2018

Lille (France), 19 September 2018 - ALZPROTECT, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, today announces that it has launched a study on the effect of food intake for its drug candidate AZP2006.

The dietary effect study is a randomized, single-dose crossover study to investigate the potential effects of food intake on the pharmacokinetics of AZP2006 administered orally to 14 healthy volunteers.

Previous Phase I clinical studies in 88 subjects had demonstrated that after oral administration, AZP2006 was well absorbed by the intestine and well tolerated by healthy volunteers. "This food effects study will explore the optimal timing of AZP2006 versus food intake. On the other hand, the results will make it possible to follow up on the next phase 2 clinical study in patients, planned for 2019 " said Philippe Verwaerde, president and scientific director of Alzprotect.

All news